ReviewJournal of clinical medicine2021
Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Platelet Levels Associated With Bleeding Risk for Dental Interventions: A Systematic Review.Oral diseases · 2026Pooled it
- Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study.Scientific reports · 2026Trial
- Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial.Annals of medicine · 2023Trial
- Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.Hepatology international · 2023Trial
- Article
- Intrahepatic Platelets Orchestrate Microenvironmental Remodelling and Cellular Crosstalk in Liver Fibrosis.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Serum biomarker analysis may guide management of anemia in patients with chronic liver disease.Frontiers in medicine · 2026Article
- Platelet optimization in high-risk ALBI grade 3 patients undergoing invasive procedures: real-world evidence from lusutrombopag therapy.Frontiers in pharmacology · 2026Article
- Coagulation abnormalities in pediatric anemia clinical and laboratory correlates for risk stratification and risk assessment.Annals of medicine and surgery (2012) · 2026Review
- Recombinant human thrombopoietin for chronic liver disease-associated thrombocytopenia with or without concomitant infections: a real-world retrospective study.Frontiers in pharmacology · 2026Article
- Uncovering prognostic biomarkers through a pharmacovigilance study: the case of RDW.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- The Mechanisms behind Thrombocytopenia in Patients with Portal Hypertension and Chronic Liver Disease.Journal of clinical and translational hepatology · 2025Review
- Optimizing perioperative care in liver disease: the role of TPO-receptor agonists.Annals of medicine and surgery (2012) · 2025Article
- From Therapy to Toxicity: A Rare Case of Acute Piperacillin/Tazobactam-Associated Drug-Induced Liver Injury.Cureus · 2025Article
- Clinical Outcomes of Oral Anticoagulation in Elderly East Asian Patients with Atrial Fibrillation: A Retrospective Single-Center Study.Life (Basel, Switzerland) · 2025Article
- Platelet Functional Profile Is Altered in Metabolic Dysfunction-Associated Steatotic Liver Disease.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Beyond the Limits of Conventional Coagulation Tests: A Comprehensive Overview of ACLF-Related Coagulopathies.Journal of clinical medicine · 2025Review
- Comparative analysis of thrombocytopenia incidence in patients treated with generic vs. brand-name linezolid: a cohort study utilizing hospital electronic medical records.Frontiers in pharmacology · 2025Article
- Early prediction of acute-on-chronic liver failure development in patients with diverse chronic liver diseases.Scientific reports · 2024Article
- [Clinical research progress of lusutrombopag for the treatment of thrombocytopenia in chronic liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
Abstract
Thrombocytopenia, defined as a platelet count <150,000/μL, is the most common complication of advanced liver disease or cirrhosis with an incidence of up to 75%. A decrease in platelet count can be the first presenting sign and tends to be proportionally related to the severity of hepatic failure. The pathophysiology of thrombocytopenia in liver disease is multifactorial, including (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.